The Latest Cardiac and Vascular News
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to…
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE…
New findings from the SINGLE SHOT CHAMPION trial (NCT05534581), presented at EHRA 2025 and published in the New England Journal of Medicine, showed the FARAPULSE™ Pulsed Field Ablation (PFA) System to be superior in reducing atrial arrhythmia (AA) recurrence for treating symptomatic, drug-refractory paroxysmal atrial fibrillation (PAF) compared to the Artic Front Advance™ cardiac cryoablation catheter. […]
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and…
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and…
MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., […]
MARLBOROUGH, Mass. and AMSTERDAM, Aug. 27, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed Field Ablation (PFA) System*, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation (AF). The study is the first […]
Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™ Cryoablation System* meet safety and effectiveness endpoints MARLBOROUGH, Mass., May 20, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company’s key electrophysiology […]
Acquisition complements company’s electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include […]
– FARAPULSE becomes first company in the world to commercialize a cardiac PFA system – MENLO PARK, Calif., Jan. 29, 2021 /PRNewswire/ – FARAPULSE Inc. (“FARAPULSE” or “the Company”) today announced that it has received the Conformité Européene (CE) Mark for its FARAPULSE Pulsed Field Ablation (PFA) system for the treatment of […]
